News
New data demonstrates long-term benefit of Crysvita for XLH patients
Kyowa Kirin’s Crysvita (burosumab) has new long-term data showing ‘sustained’ benefits for adults living with the rare genetic metabolic bone disease X-linked hypophosphataemia (XLH).